Switch of Intravitreal Therapy for Macular Edema Secondary to Retinal Vein Occlusion from Anti-VEGF to Dexamethasone Implant and Vice Versa

Table 1

Patients’ baseline characteristics and reason for switch of intravitreal therapy.

	Anti-VEGF to dexamethasone	Dexamethasone to anti-VEGF	Dexamethasone
BRVO	73% (22)	67% (4)	45% (5)
CRVO	20% (6)	17% (1)	55% (6)
Gender (% female)	50%	50%	45%
Age (at baseline [years])	69 ± 10	70 ± 13	74 ± 12
BCVA before switch (mean ± SD [logMAR])	0.42 ± 0.28	0.55 ± 0.34	1.07 ± 0.69
BCVA before switch (mean ± SD [logMAR])	0.36 ± 0.31	0.52 ± 0.45	0.88 ± 0.50
Number of intravitreal injections before switch (median, quartiles)	6 [3.25; 10]	1.5 [1;2]
Reason for switch
(i) Deterioration	40% (12)	33% (2)
(ii) Stagnation	47% (14)	67% (4)
(iii) Patients’ choice	3% (1)	0
(iv) IOP decompensation	3% (1)	0
(v) Not known	7% (2)	0

BRVO/CRVO: branch/central retinal vein occlusion; BCVA: best-corrected visual acuity.